<DOCUMENT>
<TYPE>EX-10.59
<SEQUENCE>3
<FILENAME>d937895dex1059.htm
<DESCRIPTION>EX-10.59
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.59</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.59 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 2 TO SUBLICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT to the Sublicense Agreement effective as of November&nbsp;20, 1997 (the &#147;Sublicense Agreement&#148;) is made as of
April&nbsp;10, 2001 by and between TITAN PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (hereinafter
&#147;TITAN&#148;), and NOVARTIS PHARMA A.G., a corporation organized under the laws of Switzerland and having its principal office at Lichtstrasse 35, CH 4002 Basel, Switzerland (hereinafter &#147;NOVARTIS&#148;). Capitalized terms used in this
Amendment shall have the same meanings set forth in the Sublicense Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, TITAN and NOVARTIS desire to amend the Sublicense Agreement to add Japan to the scope of the sublicense and to incorporate certain
related modifications to the terms and conditions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. Section&nbsp;1.21 of the Sublicense Agreement is
hereby deleted in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;1.21 &#147;TERRITORY&#148; shall mean all countries
and territories of the world; provided that any country(ies) in which this Sublicense Agreement is terminated shall be removed from the scope of this definition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2. <U>Grant</U>. Section&nbsp;2.1(f) is hereby deleted in its entirety and replaced with the following </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;2.1(f) TITAN and its AFFILIATES and SUBLICENSEES shall be entitled to utilize the PATENTS and KNOW-HOW in the FIELD
within the TERRITORY for the development and manufacture of COMPOUND and PRODUCT for marketing, distribution and sale outside of the TERRITORY (those countries where NOVARTIS&#146; rights under this Sublicense Agreement have been terminated). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3. <U>Payments and Royalties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a. Section&nbsp;3.1 of the Sublicense Agreement is hereby amended by deleting subsection (d)&nbsp;in its entirety and adding the following new
subsections (d), (e)&nbsp;and (f): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(d) An upfront license fee of **** shall be paid by NOVARTIS to TITAN in cash
within **** of both parties execution of this Amendment Agreement. An additional license fee of **** shall be payable by NOVARTIS to TITAN within **** after submission by TITAN to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">****C<SMALL>ERTAIN</SMALL>
<SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL> C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL>
<SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL> <SMALL>PORTIONS</SMALL>. </P>
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOVARTIS of an Invoice one time only upon annual NET SALES in **** reaching
****. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(e) Upon submission by TITAN to NOVARTIS of an Invoice therefor, a milestone payment of **** shall be payable
one time only by NOVARTIS to TITAN as follows: (i)&nbsp;**** shall be paid in cash upon receipt by NOVARTIS, its AFFILIATE or SUBLICENSEE of notification from the **** that PRODUCT is approved for **** in **** by NOVARTIS, its AFFILIATE or
SUBLICENSEE (or their designee) for schizophrenia or other psychiatric disorders; and (ii)&nbsp;**** shall be paid in cash within **** after receipt of such notification. The **** payment provided for herein shall, unless otherwise expressly
provided for herein, be non-refundable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(f) NOVARTIS shall notify TITAN in writing **** prior to NOVARTIS&#146;
estimated achievement of each milestone event described in Sections 3.1(b), 3.1(c)(i) and 3.1(e) above. Upon the receipt of such notification, TITAN shall send NOVARTIS an Invoice for the milestone payment due as a result of the achievement of such
milestone event, and NOVARTIS shall make each such payment within **** of the achievement of the milestone event for which payment is due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b. Section&nbsp;3.3 of the Sublicense Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;3.3(a) As consideration for the sublicense granted to NOVARTIS in this Sublicense Agreement with respect to all of the
TERRITORY ****, NOVARTIS shall pay to TITAN, in those countries where, and for the period, PATENTS claiming a priority date of May&nbsp;19,1989 and December&nbsp;29, 1989 in a particular country in the TERRITORY **** for which a patent had been
granted validly claiming Iloperidone or the manufacture, formulation or the use thereof for use in the FIELD exist: (i)&nbsp;a twenty-three percent (23%)&nbsp;royalty on annual NET SALES of PRODUCT in the TERRITORY **** up to Two Hundred Million
Dollars ($200,000,000), and (ii)&nbsp;a twenty-five percent (25%)&nbsp;royalty on annual NET SALES of PRODUCT in the TERRITORY **** in excess of Two Hundred Million Dollars ($200,000,000); in each case on NOVARTIS&#146;, its AFFILIATES&#146; and
SUBLICENSEES&#146; annual NET SALES of PRODUCT in the TERRITORY ****. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As consideration for the sublicense granted to
NOVARTIS in this Sublicense Agreement with respect to ****, NOVARTIS shall pay to TITAN: (i)&nbsp;a **** percent (****%) royalty on annual NET SALES of PRODUCT in **** up to ****, and (ii)&nbsp;a **** royalty on annual NET SALES of PRODUCT in ****
in excess of **** </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P> 

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">****C<SMALL>ERTAIN</SMALL> <SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL>
<SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL> C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL>
<SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL> <SMALL>PORTIONS</SMALL>. </P>
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">****; in each case on NOVARTIS&#146;, its AFFILIATES&#146; and
SUBLICENSEES&#146; annual NET SALES of PRODUCT in ****. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4. <U>Development</U>. Section&nbsp;5.5 of the Sublicense Agreement is hereby
amended by deleting the second sentence of the paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5. <U>Exchange of Information and Confidentiality</U>. Section&nbsp;6.3 of the
Sublicense Agreement is hereby amended by deleting the second sentence of the paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6. <U>Appendix A</U>. The following patents
shall be added to Appendix A: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="15%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="15%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="13%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="13%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="13%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="13%"></TD> 
<TD VALIGN="bottom"></TD> 
<TD WIDTH="12%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" ALIGN="center">****</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7. <U>Effectiveness</U>. This Amendment shall be deemed effective as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a.
<U>Agreement Amended</U>. Subject to the provisions of this Section&nbsp;7, this Amendment shall be deemed to be an amendment to the Sublicense Agreement. All references to the Sublicense Agreement in any other document, instrument, agreement or
writing hereafter shall be deemed to refer to the Sublicense Agreement as amended hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b. <U>Successors and Assigns</U>. This
Amendment shall be binding upon and inure to the benefit of TITAN and NOVARTIS and their respective successors and assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c.
<U>Governing Law</U>. This Amendment shall be deemed to have been made in the State of New York and its form, execution, validity, construction and effect shall be determined in accordance with the laws of the State of New York (without regard to
New York&#146;s or any other jurisdictions&#146;s conflict of laws principles). </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P> 

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">****C<SMALL>ERTAIN</SMALL> <SMALL>INFORMATION</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL>
<SMALL>OMITTED</SMALL> <SMALL>AND</SMALL> <SMALL>FILED</SMALL> <SMALL>SEPARATELY</SMALL> <SMALL>WITH</SMALL> <SMALL>THE</SMALL> C<SMALL>OMMISSION</SMALL>. C<SMALL>ONFIDENTIAL</SMALL> <SMALL>TREATMENT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL>
<SMALL>REQUESTED</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>OMITTED</SMALL> <SMALL>PORTIONS</SMALL>. </P>
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereby have executed this Agreement by
proper persons thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right"> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">

 
<TR> 
<TD WIDTH="12%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="43%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="43%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="5">NOVARTIS PHARMA A.G.</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD> 
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Markus Goebel</TD> 
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD> 
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gisela Schelling</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Markus Goebel</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Gisela Schelling</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Head Nervous System BD&amp;L</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top">Legal Counsel</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16" COLSPAN="5"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" COLSPAN="5">TITAN PHARMACEUTICALS, INC.</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="4"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">By:</TD> 
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD> 
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Louis R. Bucalo M.D.</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Name:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" COLSPAN="3">Louis R. Bucalo, M.D.</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Title:</TD> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="top" COLSPAN="3">Chairman, President and CEO</TD></TR>
</TABLE></DIV> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P> 
 
</BODY></HTML>
</TEXT>
</DOCUMENT>
